Pay in 4 interest-free payments of $5.60 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
According to the 2025 study on minimizing muscle loss, strength training and adequate protein were identified as key factors in maintaining muscle while losing weight on GLP-1s
In Part 2, we examined how incretin-based treatments for obesity and diabetes could reshape future patterns of morbidity and mortality
Whats more, it resulted in a 20% lower risk of death from any cause
10.1146/annurev-cellbio-101512-122326 Annu
Who Should Pay Attention to This Research This trial is most immediately relevant to: Older adults with known risk factors for cognitive decline particularly those with obesity, type 2 diabetes, high blood pressure, or cardiovascular disease who are also candidates for GLP-1 therapy Researchers and clinicians working at the intersection of metabolic health and cognitive aging People currently taking GLP-1 medications for diabetes or obesity who have wondered whether the drugs may offer cognitive benefits Caregivers and family members of older adults who are monitoring cognitive health and looking for potential preventive strategies Symptoms and Warning Signs to Watch For The PROTECT-Cog Study is designed for prevention it targets people who are at risk for cognitive decline but have not yet been diagnosed with dementia
This innovative system supports weight & appetite management, enhances mental clarity and focus, boosts cardiovascular health, and promotes a healthy metabolism
